Health Payer Intelligence January 13, 2020
CVS Health recommends value-based contracting, coordinated care, and other strategies to lower gene therapy costs.
Eleven gene therapies could cost an individual as much as $45 billion over the next five years, but payers can bring that cost to a more manageable price range through methods such as value-based contracting and coordinated care, CVS Health and Aetna wrote in a recent white paper.
“The role of CVS Health—and Aetna as a health insurer—is to reduce the costs of therapy, while ensuring appropriate utilization of cutting-edge therapies,” the paper started.
The cost for gene therapies can vastly differ, the report authors said. In vivo therapies, for example, are less costly and use a gene-carrying virus to spread the correct gene through...
Today's Sponsors
Today's Sponsor